FDA Approves Boston Scientific’s Synergy Bioabsorbable Polymer
The FDA has approved Boston Scientific’s Synergy Bioabsorbable Polymer for the treatment of coronary artery disease.
The device, which provides synchronized drug and polymer absorption, is designed to aid in more rapid and complete arterial healing and reduce the risk of complications associated with long-term polymer exposure.
The polymer remains on the stent of current DES devices after the drug is delivered, which could result in delayed healing caused by inflammation, as well as neoatherosclerosis and stent thrombosis.
The Synergy stent received CE Mark in 2012. — Michael Cipriano